EP2282732A2 - Verwendung von olivenölextrakt zur kontrolle der hautalterung - Google Patents

Verwendung von olivenölextrakt zur kontrolle der hautalterung

Info

Publication number
EP2282732A2
EP2282732A2 EP09728858A EP09728858A EP2282732A2 EP 2282732 A2 EP2282732 A2 EP 2282732A2 EP 09728858 A EP09728858 A EP 09728858A EP 09728858 A EP09728858 A EP 09728858A EP 2282732 A2 EP2282732 A2 EP 2282732A2
Authority
EP
European Patent Office
Prior art keywords
oleocanthal
olive oil
derivative
use according
oil extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09728858A
Other languages
English (en)
French (fr)
Inventor
Cyril Estanove
François PRUVOST
Jean-Claude Allart
Frédéric SALDMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bc Development Sa
Sprim
Original Assignee
Bc Development Sa
Sprim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bc Development Sa, Sprim filed Critical Bc Development Sa
Publication of EP2282732A2 publication Critical patent/EP2282732A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to a novel composition based on extracts derived from olive oil, and more particu larly to ⁇ oleocanthal and derivatives oleocanthal, and its use in cosmetics and dermatology for the control of skin aging and its effects.
  • the skin is an essential organ of life, which fulfills several functions whose quality has a decisive influence on the health of every individual.
  • the skin is a real barrier to the environment, the effectiveness of which determines the maintenance of a good homeostatic balance.
  • This cutaneous barrier is subjected to incessant aggressions, and the quality of its defenses is thus a major element for the effectiveness of its protection.
  • the skin constitutes a living anatomical barrier between the body and its environment, and it comprises several integrated layers, namely a superficial layer constituted by the epidermis, and deeper layers forming the dermis and hypodermis, and each of these layers has specific properties allowing the whole to react and adapt to the conditions of its environment.
  • the human epidermis is particularly well adapted to play its essential function of "barrier", it limits the entry of external agents and participates in the general homeostasis of the body by regulating the loss of transepidermal water.
  • the epidermis is mainly composed of keratinocytes
  • the dermis is thicker, and consists mainly of collagen, elastin and proteoglycans. These three types of molecules are synthesized by dermal fibroblasts. Collagen fibers provide the strength and texture of the skin, elastin is responsible for elasticity, and proteoglycans play a major role in the structure and hydration of the skin. Other cells such as macrophages and leucocytes are also present in the dermis layer.
  • the hypodermis is the deepest layer of skin, and contains lipid-producing fat cells so that the subcutaneous tissue can make a fat layer that protects muscles, bones, and internal organs from shock.
  • the stratum corneum of the epidermis has a structure composed of corneocytes, flattened cells, which have neither nucleus nor cytoplasmic organelles. These cells are therefore biologically dead but still remain active. They result from the final phase of keratinocyte differentiation, and they are filled with keratins and surrounded by a
  • lipophilic "cement” consisting of the lipids that fill the extracellular spaces.
  • corneocytes we distinguish two different layers of corneocytes, namely the compact layer where the corneocytes, connected to each other by the corneododesmosomes, provide the barrier function, and the desquamating layer where the degradation of these corneodesmosomes causes the phenomenon of desquamation.
  • the corneocytes are thus eliminated continuously by this natural phenomenon or as a result of external aggression.
  • the renewal of the epidermis is a balance between the loss of superficial cells, corneocytes, and the formation of new epidermal cells in a process of cellular differentiation.
  • the thickness of the stratum corneum does not decrease with age, but the cohesion of corneocytes becomes unequal, leading to a phenomenon of accumulation contributing to give a xerotic aspect to the integument.
  • Skin aging is accompanied by a decrease in lipid levels in the stratum corneum.
  • the water content of the subcutaneous tissue decreases with age.
  • the stratum corneum constitutes the essential element of the cutaneous barrier whereas the dermal structures, for an uninjured skin, participate only slightly in this global barrier function.
  • aging of the skin, in particular of the stratum corneum results from factors that may be intrinsic and extrinsic.
  • the intrinsic factors correspond to the chronological aging.
  • the chronological aging is materialized by a decrease in the proliferation of keratinocytes (which are the cells of the epidermis), and dermal fibroblasts, and therefore their renewal. These senescent cells no longer have the possibility of leaving the G1 phase of the cell cycle and thus of dividing by mitosis. Become resistant to cell death (apoptosis), they accumulate in the dermis and epidermis, and they tend to atrophy.
  • extrinsic factors of skin aging can be related to the environment, including friction, washing, detergents, free radicals and climatic aggressions, in particular exposure to the sun and temperature variations, these phenomena being able to contribute to accelerate the degradation of the barrier function of the epidermis and collagen of the dermis.
  • compositions in the form of serums, creams and lotions containing alpha-hydroxy acids or retinoids applied regularly to gradually reduce the number of lines and wrinkles, or even topical compositions based on Lys-Thr-Thr-Lys-Ser type penta peptides, promoting the synthesis of collagen and glycosaminoglycans and providing an effect on cutaneous regeneration as described in FR-A-2,783,169.
  • Implants of collagen and hyaluronic acid have also been proposed to hide expression lines around the eyes or mouth, dermabrasion and chemical peels to remove the top layer of damaged skin, cosmetic surgery or a facelift to resuscitate sagging skin, or restructure with a carbon dioxide laser to remove fine lines.
  • Olive oil contains in particular monounsaturated fatty acids (oleic acid) as well as phenolic compounds with antioxidant properties which have the effect of retarding the oxidation of LDL lipoproteins.
  • phenolic compounds there are phenolic alcohols such as tyrosol and hydroxy-tyrosol, benzoic acids, caffeic and They are esterified with tyrosol and hydroxytyrosol, as well as flavonoids such as flavones and flavonols.
  • the patent application JP 2001181198 describes a cosmetic composition having an anti-aging effect and skin lightening, containing a plant extract from the manufacture of olive oil and various excipients. It is also known from DE 102006041486 that a lotion based on olive oil, Cera alba and royal jelly can be used to treat certain dermatological conditions.
  • oleocanthal properties of oleocanthal are also described in WO 2006122128, and they show that oleocanthal could be considered as a general anti-inflammatory drug, orally, in the same indications as ibuprofen, especially in rheumatology.
  • Oleocanthal, or deacetoxy-ligstroside aglycone has been detected in olive oils from various sources, more particularly in virgin olive oil obtained by first cold pressing, at very low concentrations which generally vary from 20 to 200 ppm (mass), or from 0.00-2 to 0.02% by weight, depending the source of the olive oil.
  • Oleocanthal may be represented by the following general formula (I):
  • Oleuropein found in fruits and mainly in olive leaves, is a glycoside represented by the general formula (II) below:
  • oleuropein in food or pharmaceutical compositions for stimulating bone mineralization in humans or animals has been proposed in WO 2004091591.
  • the antiviral activity of certain oleuropein derivatives has also been described in US Pat. US Patent 6,455,580.
  • Derivatives such as oleuropein aglycone, having antioxidant properties, and its dialdehyde form can also be extracted from olive oil.
  • R is a hydrogen atom or a hydroxy group
  • oleocanthal like most polyphenolic compounds naturally present in vegetable oils, is a very fragile product, easily destroyed by heat and oxidation.
  • the subject of the present invention is therefore the use of an olive oil extract containing oleocanthal and / or a derivative of general formula (A) below.
  • R represents a hydrogen atom or a hydroxyl group, as well as extracts containing them, in cosmetics and in dermatology for the control and regulation of skin aging.
  • the invention more particularly relates to the use of an olive oil extract containing oleocanthal and / or a derivative for the preparation of cosmetic and / or dermatological compositions for controlling and regulating cutaneous aging.
  • the subject of the invention is also the combined use of oleocanthal, and / or of derivatives of formula (A) above, and of oleuropein and a cosmetic and / or dermatological composition associating them, useful in particular for ensuring control and regulation of skin aging.
  • the subject of the invention is also the use of derivatives of formula (A), more particularly oleocanthal, or of olive oil extracts containing them, for the preparation of a medicament for the treatment of ichthyosis and ichthyotic states.
  • the olive oil extract used in the present invention is an extract enriched in oleocanthal, as indicated below.
  • the studies carried out by the Applicant have shown that the effectiveness of compositions based on derivatives of formula (A) above, in particular oleocanthal, in the cosmetic and / or dermatological treatment of skin aging results from several mechanisms, in particular: a mechanism of inhibition of keratinocyte hyperproliferation reactive to environmental aggressions (to the detriment of the proliferation of keratinocytes); a mechanism for stimulating differentiation of keratinocytosis and regulation of desquamation; a lipid synthesis mechanism.
  • the demonstration of these actions demonstrates that oleocanthal is able to control the skin permeability disorders generated by the deficiency of the effect. barrier induced by intrinsic skin aging and aggravated by photoinduced aging.
  • the oleocanthal as well as the derivatives described above, are preferably used in the form of olive oil extract enriched with oleocanthal.
  • the extract generally also contains the dialdehyde of decarboxymethyl oleuropein aglycon, represented by the formula (A) where R is a hydroxyl group.
  • This derivative provides an antioxidant complementary effect useful for the composition of the present invention. Its concentration in the extract can be generally of the order of 5 to 20%.
  • compositions of the invention may be between 0.1 mg and 500 mg for the oleocanthal and the derivative, used alone or, preferably, in combination.
  • the composition comprises in combination 10 to 99.5% of oleocanthal and 0.5 to 90% of derivative per 100 g of total composition.
  • the composition contains between 0.3 mg and 3 g of olive oil extract containing 30 to 35% oleocanthal and 5 to 20% of dialdehyde of decarboxymethyl oleuropein agly ⁇ one.
  • the compositions that can be used in the present invention can be in any of the usual forms suitable for topical local administration.
  • compositions for topical application may be in the form of oily or hydro-alcoholic solutions, spraying solutions, dispersions, serums, gels or lipogels, suspensions, liquid or semi-liquid emulsions.
  • liquids for example a milk
  • solid or semi-solid shampoo or formulation of the spot-on type.
  • the emulsions may be of the oil-in-water (O / W) or water-in-oil (W / O) type, for example gels or creams.
  • a lipid medium is preferably used, for example a lipophilic solvent such as 1,2-O-isopropylideneglycerol (Solketal) and diethylene glycol monoethyl ether (Transcutol), more compatible in particular with the use of an extract of olive oil.
  • a lipophilic solvent such as 1,2-O-isopropylideneglycerol (Solketal) and diethylene glycol monoethyl ether (Transcutol), more compatible in particular with the use of an extract of olive oil.
  • Solketal 1,2-O-isopropylideneglycerol
  • Transcutol diethylene glycol monoethyl ether
  • Another penetration adjuvant that can be used advantageously in the invention is tetrahydropiperine obtained from pepper, and is commercially available (Cosmoperine®).
  • excipients and carriers that can be used in the compositions according to the present invention are those commonly used in preparations for cosmetic or dermatological use, and they are chosen according to the form of administration chosen.
  • the choice of the dose used and the duration of the treatment is determined by the practitioner, but generally a composition dosed between 10 and 500 mg of olco ⁇ nthal can be used at a rate of or two daily applications for a period of a few days to a few weeks depending on the condition of the skin to be treated.
  • compositions of the invention based on oleocanthal, or olive oil extract enriched in oleocanthal.
  • formulations containing 0.05 to 0.5% of oleochalhal in the form of galenical preparations for local use on the skin of volunteer patients, without penetration adjuvant, with one or two applications per day. for 15 days demonstrated a marked improvement in the cutaneous barrier effect manifested by an improvement of the resistance to detergents and degreasers (acetone), a reduction of the insensible loss in water (that is to say the evaporation through the skin, measured with Towl hygrometer).
  • the skin is more supple and its luster strengthened. Surprisingly, this effect is all the more marked as the age of the patient is high. In addition, the effect is dose-dependent from the threshold of about 0.05%.
  • compositions according to the invention can be used not only for controlling and regulating cutaneous aging, but also for treating certain skin conditions such as icthyosiform states, orthoergic dermatitis induced by chemical or physical aggression. , and atopic dermatitis.
  • a fluid cream for external application is prepared according to conventional techniques and its formulation is as follows. Phase A, B, C, D, and E containing the following constituents (% by weight) were prepared and mixed to obtain a fluid cream. Phase A: 61, 70% Water 0, 10 EDTA disodium (Dissolvine Na2)
  • composition B containing the following constituents (% by weight) was prepared
  • Phase C 5.00 glycerin 1.67 olive oil extract with 33.4% oleocanthal
  • This cream can be applied evenly to the skin once or twice a day for 2 to 3 weeks.
  • a lotion having the following composition (% by weight) is prepared:
  • the following phases A, B, C and D were prepared and mixed to form a serum.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
EP09728858A 2008-03-21 2009-03-19 Verwendung von olivenölextrakt zur kontrolle der hautalterung Withdrawn EP2282732A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0801572A FR2928837B1 (fr) 2008-03-21 2008-03-21 Utilisation d'un extrait d'huile d'olive pour le controle du vieillissement cutane
PCT/FR2009/000291 WO2009122045A2 (fr) 2008-03-21 2009-03-19 Utilisation d'un extrait d'huile d'olive pour le controle du vieillissement cutane

Publications (1)

Publication Number Publication Date
EP2282732A2 true EP2282732A2 (de) 2011-02-16

Family

ID=40084397

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09728858A Withdrawn EP2282732A2 (de) 2008-03-21 2009-03-19 Verwendung von olivenölextrakt zur kontrolle der hautalterung

Country Status (3)

Country Link
EP (1) EP2282732A2 (de)
FR (1) FR2928837B1 (de)
WO (1) WO2009122045A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11684563B2 (en) 2021-01-14 2023-06-27 Doncab Plant derived active ingredient comprising plant extracts

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2146921C1 (ru) * 1997-11-05 2000-03-27 Рязанский областной клинический кожно-венерологический диспансер Мазевая композиция, стимулирующая регенерацию эпителия
JP2001181198A (ja) * 1999-10-14 2001-07-03 Nisshin Oil Mills Ltd:The 美肌剤、皮膚の抗老化剤、美白剤および皮膚外用剤
KR20060053633A (ko) * 2004-11-17 2006-05-22 주식회사 코리아나화장품 예덕나무 추출물, 아보카도 오일 및 올리브 오일을유효성분으로 함유하는 피부 주름 개선용 화장료 조성물
CN100352421C (zh) * 2005-07-12 2007-12-05 沈阳何氏眼科产业发展有限公司 祛皱眼霜
DE202005011537U1 (de) * 2005-07-22 2006-01-12 Haaks, Ingrid-Anne Kosmetisches Gesichts-Öl
DE102006041486B4 (de) * 2006-09-02 2011-04-28 Küchenmeister, Kurt-Dieter Kosmetische und dermatologische Zubereitung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009122045A2 *

Also Published As

Publication number Publication date
FR2928837A1 (fr) 2009-09-25
FR2928837B1 (fr) 2010-05-07
WO2009122045A2 (fr) 2009-10-08
WO2009122045A3 (fr) 2009-12-03

Similar Documents

Publication Publication Date Title
WO2012085230A1 (fr) Extrait de parties aeriennes de gynandropsis gynandra ou cleome gynandra et compositions cosmetiques, dermatologiques ou pharmaceutiques le comprenant
EP0831865B1 (de) Myrteextrakt enthaltendes haarpflegemittel, verfahren zur herstellung und verwendung insbesondere für eine antischuppenbehandlung
JP4005917B2 (ja) 角質層の機能向上を目的とするコレステロール硫酸およびアミノ糖の組成物
EP4203985B1 (de) Verwendung von silybum marianum (l.) gaertn. öl zur stärkung der barrierefunktion der haut
FR2948877A1 (fr) Composition pour la protection et la regeneration de la peau
WO2025087637A1 (en) Pseudostellaria heterophylla root extract and use thereof
EP2282732A2 (de) Verwendung von olivenölextrakt zur kontrolle der hautalterung
EP2200432A2 (de) Antimikrobielle zusammensetzung zur verwendung in kosmetik und dermatologie
FR3021539A1 (fr) Composition cosmetique et/ou dermatologique comprenant un extrait vegetal et un activateur de genes
EP2811978B1 (de) Verwendung eines extraktes aus der apfelbaumrinde zur kosmetischen verhinderung von alterserscheinungnen der haut
EP2811977B1 (de) Verwendung eines apfelbaumblattextraktes in einer kosmetischen haut-straffungs zusammensetzung
EP4009940B1 (de) Neue kosmetische verwendung eines extraktes von epilobium angustifolium
EP4494647A1 (de) Enkeextrakt aus silybum marianum (l.) gaertn. zur behandlung oder prävention von hautrötungen
FR2918278A1 (fr) Utilisation de l'oleocanthal dans le traitement de l'inflammation cutanee.
EP2694028A2 (de) Zusammensetzung auf der basis von chaulmoograöl und tribulus terrestris für hautpigmentierung
FR2986707A1 (fr) Composition comprenant un extrait de jus de pomme pour le confort cutane.
FR2973247A1 (fr) Composition a base de samanea saman pour la protection de la peau.
FR3014318A1 (fr) Composition a usage topique comprenant au moins un extrait de rhus coriaria l
FR3011179A1 (fr) Utilisation d'un extrait d'artemisia orientalis dans une composition cosmetique amincissante
FR2912054A1 (fr) Composition cosmetique comprenant une association de trois formes de vitamine c
FR2983076A1 (fr) Composition topique comprenant une association d'au moins un extrait d'algue bleue avec au moins un acide alpha hydroxyle ou un de ses sels

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111005